COMBINATION OF CHEMOTHERAPY AND HORMONE-THERAPY IN ADVANCED BREAST-CANCER

被引:0
|
作者
MERKLE, E [1 ]
BAR, I [1 ]
HENKE, A [1 ]
BUHNER, M [1 ]
WILDT, L [1 ]
MARTUS, P [1 ]
LANG, N [1 ]
机构
[1] UNIV ERLANGEN NURNBERG,INST MED STAT & DOKUMENTAT,W-8520 ERLANGEN,GERMANY
关键词
ADVANCED BREAST CANCER; COMBINED THERAPY; DECAPEPTYL(R); RESPONSE RATE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In a prospective study at the Department of Obstetrics and Gynaecology, University of Erlangen, patients with advanced breast carcinoma were treated with a combination of chemotherapy and hormone therapy. Patients received one injection of Decapeptyl(R) in a 28 days interval. At day 12 and 13 of the treatment cycle 40 mug of ethinylestradiol were applicated followed by intravenous chemotherapy with 500 mg/m2 fluorouracil, 10 mg/m2 mitoxantrone and 500 mg/m2 cyclophosphamide took place on day 14. 39 patients were integrated in this study. All of these patients were evaluable regarding the side-effects and 36 patients concerning the response rate. In case of response after 6 cycles the interval between the chemotherapy was prolonged to 6 weeks and the Decapeptyl(R) injections remained in a 4 weeks interval. 15 patients received this combined therapy as a first-line therapy, 24 patients as a second-line therapy or third-line therapy. 2 patients had a complete remission, 14 patients had a partial remission. The objective response rate (CR+PR) was therefore 44 %. In 8 patients the response was classified as no change, consequently the total response rate (CR + PR + NC) was 67 %. 12 patients showed a progression (33 %), 2 patients with several previous treatments suffered an early progress. 3 patients did not finish the therapy. The median response duration was 9 months and the median follow up time until now is 13 months; 24 patients died. Therapy related side-effects were tolerable. As the most frequent side-effect bone marrow suppression were observed. Subjective, for the patients most inconvenient side-effects like nausea, vometing, and alopecia seldomly appeared. The combination of chemotherapy and hormone therapy achieved with a good toleration response rates, which are compatible to international standards of chemotherapy. The exspectations to achieve a better remission rate by a combination of chemotherapy and hormone therapy rather than chemotherapy alone were not fulfilled in this studie.
引用
收藏
页码:220 / 223
页数:4
相关论文
共 50 条
  • [1] HORMONE-THERAPY FOR ADVANCED BREAST-CANCER
    ESPIE, M
    BULLETIN DU CANCER, 1994, 81 (10) : 5 - 7
  • [2] COMBINATION OF HORMONE-THERAPY AND CHEMO-THERAPY IN ADVANCED BREAST-CANCER
    KIANG, DT
    FRENNING, DH
    GAY, J
    KENNEDY, BJ
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 407 - 407
  • [3] PALLIATIVE HORMONE-THERAPY IN ADVANCED BREAST-CANCER
    SCHRODER, W
    GYNAKOLOGE, 1993, 26 (02): : 131 - &
  • [4] SEQUENTIAL HORMONE-THERAPY FOR ADVANCED BREAST-CANCER
    VONROENN, JH
    BONOMI, PD
    GALE, M
    ANDERSON, KM
    WOLTER, JM
    ECONOMOU, SG
    SEMINARS IN ONCOLOGY, 1988, 15 (02) : 38 - 43
  • [5] HORMONE-THERAPY FOR BREAST-CANCER
    NAMER, M
    BULLETIN DU CANCER, 1991, 78 (11) : 1 - 8
  • [6] NEW HORMONE-THERAPY FOR BREAST-CANCER
    不详
    SCIENCE NEWS, 1983, 123 (13) : 203 - 203
  • [7] ADJUVANT HORMONE-THERAPY IN BREAST-CANCER
    GORINS, A
    SEMAINE DES HOPITAUX, 1985, 61 (35-3): : 2545 - 2545
  • [8] ADJUVANT HORMONE-THERAPY IN BREAST-CANCER
    BLOMQVIST, CP
    ELOMAA, I
    RISSANEN, P
    ANNALS OF MEDICINE, 1992, 24 (02) : 91 - 96
  • [9] SECONDARY HORMONE-THERAPY FOR BREAST-CANCER
    GARCIAGIRALT, E
    AYME, Y
    CARTON, M
    DABAN, A
    DELOZIER, T
    FARGEOT, P
    GUERIN, D
    PUMOLEAU, P
    GORINS, A
    GUERIN, R
    MAILLART, P
    MAURIAC, L
    MAYLEVIN
    METZ, R
    NAMER, M
    OLIVIER, JM
    POMMATEAU, E
    PUJADELAURAINE, L
    ROUESSE, J
    SERROU, B
    VITSE, M
    ZYLBERAIT, B
    POUILLART, P
    BULLETIN DU CANCER, 1988, 75 (07) : 652 - 653
  • [10] TARGETED HORMONE-THERAPY FOR BREAST-CANCER
    JORDAN, VC
    HOSPITAL PRACTICE, 1993, 28 (03): : 55 - 62